Johannes Steiner, MD
Advanced Heart Failure and Transplant Cardiology · Portland, ORNPI 1205084605
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,098 of the $9,284 with a category attached, or 65.7%. 5 manufacturers reported payments, led by Ancora Heart, Inc. at 56.5% of the total. Reporting peaked in 2023 at $4,754 and has fallen 87.9% since, to $577 in 2025.
Across 60 payments — averaging $154.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ancora Heart, Inc.$5K
- Abiomed$2K
- Medtronic$1K
- Abbott$1K
- Cardiac Dimensions, Inc.$77
Across 20 payments — averaging $13,558 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$116K
- American Regent$85K
- AstraZeneca$62K
- Array Biopharma Inc$8K
What the payments were for
- Travel & lodging$6,09866%
- Food & beverage$3,18634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ancora Heart, Inc. | 18 | $5,246 |
| Abiomed | 15 | $1,802 |
| Medtronic(2 entities) | 9 | $1,126 |
| Abbott | 17 | $1,033 |
| Cardiac Dimensions, Inc. | 1 | $77 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AccuCinch$5,132
- Impella$1,341
- HeartWare HVAD$940
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$466
- Mitra Clip system$134
How this compares
Too few advanced heart failure and transplant cardiology providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 123 | $190,143 |
| FarxigaDapagliflozin Propanediol | 75 | $82,189 |
| JardianceEmpagliflozin | 40 | $58,089 |
| EliquisApixaban | 29 | $36,977 |
| OzempicSemaglutide | 12 | $22,403 |
| Sirolimus | 16 | $6,792 |
| Tacrolimus | 26 | $6,731 |
| Metoprolol Succinate | 111 | $2,189 |
| Torsemide | 56 | $1,588 |
| Eplerenone | 21 | $1,476 |
| Spironolactone | 103 | $1,114 |
| Omeprazole | 27 | $634 |
| Potassium Chloride | 17 | $536 |
| Ezetimibe | 15 | $524 |
| Rosuvastatin Calcium | 41 | $508 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Portland
- Jacob AbrahamPortland$331K
- Joshua RemickPortland$143K
- Christopher ChienPortland$57K
- Jenna KayPortland$37K
- Vidang NguyenPortland$27K
- Conrad MaconPortland$13K
- Luke MashaPortland$3K
- Nalini ColacoPortland$2K
- Deborah MeyersPortland$2K
- Divya SomanPortland$946
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.